vs

Side-by-side financial comparison of Emerald Holding, Inc. (EEX) and GeneDx Holdings Corp. (WGS). Click either name above to swap in a different company.

Emerald Holding, Inc. is the larger business by last-quarter revenue ($132.7M vs $121.0M, roughly 1.1× GeneDx Holdings Corp.). GeneDx Holdings Corp. runs the higher net margin — -14.6% vs -22.8%, a 8.2% gap on every dollar of revenue. On growth, GeneDx Holdings Corp. posted the faster year-over-year revenue change (26.5% vs 24.3%). Emerald Holding, Inc. produced more free cash flow last quarter ($11.7M vs $-7.4M). Over the past eight quarters, GeneDx Holdings Corp.'s revenue compounded faster (39.2% CAGR vs -0.3%).

TVS Emerald Haven Realty Limited is an Indian real estate development company headquartered in Chennai, Tamil Nadu. A subsidiary of TVS Holdings, it specializes in sustainable residential communities and urban development projects.

GeneDx is a genetic testing company that was founded in 2000 by two scientists from the National Institutes of Health (NIH), Sherri Bale and John Compton. They started the company to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which no such commercial testing was available at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, Bi...

EEX vs WGS — Head-to-Head

Bigger by revenue
EEX
EEX
1.1× larger
EEX
$132.7M
$121.0M
WGS
Growing faster (revenue YoY)
WGS
WGS
+2.3% gap
WGS
26.5%
24.3%
EEX
Higher net margin
WGS
WGS
8.2% more per $
WGS
-14.6%
-22.8%
EEX
More free cash flow
EEX
EEX
$19.1M more FCF
EEX
$11.7M
$-7.4M
WGS
Faster 2-yr revenue CAGR
WGS
WGS
Annualised
WGS
39.2%
-0.3%
EEX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EEX
EEX
WGS
WGS
Revenue
$132.7M
$121.0M
Net Profit
$-30.2M
$-17.7M
Gross Margin
69.6%
Operating Margin
-11.8%
-11.8%
Net Margin
-22.8%
-14.6%
Revenue YoY
24.3%
26.5%
Net Profit YoY
-692.2%
-424.9%
EPS (diluted)
$-0.15
$-0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EEX
EEX
WGS
WGS
Q4 25
$132.7M
$121.0M
Q3 25
$77.5M
$116.7M
Q2 25
$105.5M
$102.7M
Q1 25
$147.7M
$87.1M
Q4 24
$106.8M
$95.6M
Q3 24
$72.6M
$76.9M
Q2 24
$86.0M
$70.5M
Q1 24
$133.4M
$62.4M
Net Profit
EEX
EEX
WGS
WGS
Q4 25
$-30.2M
$-17.7M
Q3 25
$-14.4M
$-7.6M
Q2 25
$-1.4M
$10.8M
Q1 25
$15.3M
$-6.5M
Q4 24
$5.1M
$5.4M
Q3 24
$-11.1M
$-8.3M
Q2 24
$-2.8M
$-29.2M
Q1 24
$11.0M
$-20.2M
Gross Margin
EEX
EEX
WGS
WGS
Q4 25
69.6%
Q3 25
72.4%
Q2 25
69.0%
Q1 25
67.1%
Q4 24
69.2%
Q3 24
62.2%
Q2 24
60.9%
Q1 24
59.9%
Operating Margin
EEX
EEX
WGS
WGS
Q4 25
-11.8%
-11.8%
Q3 25
-10.1%
-2.8%
Q2 25
9.7%
8.7%
Q1 25
24.2%
-5.2%
Q4 24
19.5%
9.2%
Q3 24
-6.5%
-10.1%
Q2 24
7.4%
-15.0%
Q1 24
18.2%
-21.9%
Net Margin
EEX
EEX
WGS
WGS
Q4 25
-22.8%
-14.6%
Q3 25
-18.6%
-6.5%
Q2 25
-1.3%
10.5%
Q1 25
10.4%
-7.5%
Q4 24
4.8%
5.7%
Q3 24
-15.3%
-10.8%
Q2 24
-3.3%
-41.4%
Q1 24
8.2%
-32.4%
EPS (diluted)
EEX
EEX
WGS
WGS
Q4 25
$-0.15
$-0.59
Q3 25
$-0.07
$-0.27
Q2 25
$-0.01
$0.36
Q1 25
$0.08
$-0.23
Q4 24
$0.01
$0.25
Q3 24
$-0.05
$-0.31
Q2 24
$-0.03
$-1.10
Q1 24
$0.00
$-0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EEX
EEX
WGS
WGS
Cash + ST InvestmentsLiquidity on hand
$100.9M
$171.3M
Total DebtLower is stronger
$54.5M
Stockholders' EquityBook value
$338.8M
$308.2M
Total Assets
$1.2B
$523.7M
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EEX
EEX
WGS
WGS
Q4 25
$100.9M
$171.3M
Q3 25
$95.4M
$155.1M
Q2 25
$156.4M
$134.6M
Q1 25
$276.8M
$159.2M
Q4 24
$194.8M
$141.2M
Q3 24
$188.9M
$116.5M
Q2 24
$193.2M
$106.9M
Q1 24
$186.8M
$112.9M
Total Debt
EEX
EEX
WGS
WGS
Q4 25
$54.5M
Q3 25
$54.8M
Q2 25
$55.1M
Q1 25
$55.5M
Q4 24
$55.8M
Q3 24
$56.1M
Q2 24
$56.3M
Q1 24
$56.3M
Stockholders' Equity
EEX
EEX
WGS
WGS
Q4 25
$338.8M
$308.2M
Q3 25
$369.5M
$292.3M
Q2 25
$389.4M
$277.1M
Q1 25
$392.1M
$257.4M
Q4 24
$385.9M
$245.2M
Q3 24
$391.1M
$204.5M
Q2 24
$407.6M
$194.0M
Q1 24
$-90.7M
$207.2M
Total Assets
EEX
EEX
WGS
WGS
Q4 25
$1.2B
$523.7M
Q3 25
$1.2B
$493.9M
Q2 25
$1.2B
$463.9M
Q1 25
$1.2B
$446.4M
Q4 24
$1.0B
$419.4M
Q3 24
$1.1B
$408.8M
Q2 24
$1.1B
$389.1M
Q1 24
$1.1B
$394.5M
Debt / Equity
EEX
EEX
WGS
WGS
Q4 25
0.18×
Q3 25
0.19×
Q2 25
0.20×
Q1 25
0.22×
Q4 24
0.23×
Q3 24
0.27×
Q2 24
0.29×
Q1 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EEX
EEX
WGS
WGS
Operating Cash FlowLast quarter
$12.3M
$-3.1M
Free Cash FlowOCF − Capex
$11.7M
$-7.4M
FCF MarginFCF / Revenue
8.8%
-6.1%
Capex IntensityCapex / Revenue
0.5%
3.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.4M
$14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EEX
EEX
WGS
WGS
Q4 25
$12.3M
$-3.1M
Q3 25
$1.8M
$15.8M
Q2 25
$15.9M
$10.4M
Q1 25
$12.6M
$10.2M
Q4 24
$20.6M
$-3.2M
Q3 24
$9.1M
$-4.4M
Q2 24
$9.8M
$-4.5M
Q1 24
$7.3M
$-16.4M
Free Cash Flow
EEX
EEX
WGS
WGS
Q4 25
$11.7M
$-7.4M
Q3 25
$1.5M
$9.6M
Q2 25
$15.8M
$8.1M
Q1 25
$12.4M
$4.1M
Q4 24
$19.9M
$-6.2M
Q3 24
$9.0M
$-5.0M
Q2 24
$9.6M
$-5.9M
Q1 24
$7.0M
$-16.9M
FCF Margin
EEX
EEX
WGS
WGS
Q4 25
8.8%
-6.1%
Q3 25
1.9%
8.2%
Q2 25
15.0%
7.8%
Q1 25
8.4%
4.7%
Q4 24
18.6%
-6.5%
Q3 24
12.4%
-6.6%
Q2 24
11.2%
-8.3%
Q1 24
5.2%
-27.0%
Capex Intensity
EEX
EEX
WGS
WGS
Q4 25
0.5%
3.6%
Q3 25
0.4%
5.3%
Q2 25
0.1%
2.3%
Q1 25
0.1%
7.0%
Q4 24
0.7%
3.2%
Q3 24
0.1%
0.8%
Q2 24
0.2%
1.9%
Q1 24
0.2%
0.7%
Cash Conversion
EEX
EEX
WGS
WGS
Q4 25
Q3 25
Q2 25
0.96×
Q1 25
0.82×
Q4 24
4.04×
-0.59×
Q3 24
Q2 24
Q1 24
0.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EEX
EEX

Connections Segment$121.9M92%
Commerce Segment$5.5M4%
Content$5.3M4%

WGS
WGS

Diagnostic Test Third Party Insurance$101.1M84%
Diagnostic Test Institutional Customers$15.5M13%
Other$3.4M3%

Related Comparisons